Consort Medical, through its two operating subsidiaries, Aesica and Bespak, is a global, single-source drug and delivery device Contract Development and Manufacturing Organisation (CDMO). Combining world-class drug delivery device development and manufacture, together with active pharmaceutical ingredient (API), formulation development, and finished dose drug manufacture and pharmaceutical packaging services, within the Consort Medical Group, streamlines and accelerates a drugs route to market.
At the leading edge of medical innovation, Consort Medical is committed to investing in patient, clinician and customer centric innovation to create new treatments, new markets and new opportunities.
With its headquarters in the UK, the company employs approximately 2,000 people across  sites worldwide. Consort Medical is a public company quoted on the premium list of the London Stock Exchange.
Aesica is a global pharmaceutical Contract Development and Manufacturing Organisation (CDMO), offering active pharmaceutical ingredients (API) and finished dose services to pharmaceutical partners.
Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including inhalation, nasal, and injectables products; and the manufacture of devices for the point of care diagnostics market.
Group Development and Manufacturing Facilities
The Group operates facilities in King’s Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Nottingham, Queenborough and Hemel Hempstead, UK; in Monheim and Zwickau, Germany; and in Pianezza, Italy and has global sales representation in the USA, Canada, China, Japan and India.